- Case report
- Open Access
Bilateral gluteal metastases from a misdiagnosed intrapelvic gastrointestinal stromal tumor
© Pasku et al; licensee BioMed Central Ltd. 2008
Received: 17 September 2008
Accepted: 30 December 2008
Published: 30 December 2008
The location of gastrointestinal stromal tumors (GIST) outside of the gastrointestinal system is a rare event.
A 56-year old woman presented with a GIST of the pelvis was misdiagnosed and treated as a uterine leiomyosarcoma. The diagnosis was made after the CD117 (KIT) positivity in the biopsy of the excised bowel mass four years from the first presentation. During this period she presented a bilateral muscle and subcutaneous metastasis in the gluteal area.
The correct diagnosis of the extra-gastrointestinal stromal tumor is a challenge even for experienced pathologists. CD117 (KIT) positivity is the most important immunohistochemical feature in the histological diagnosis. To our knowledge a metastatic EGIST (extra-gastrointestinal stromal tumor) to the skeletal muscle bilaterally has not been described previously in the English medical literature.
Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal neoplasms that may occur in any segment of the gastrointenstinal tract. In the earlier medical literature GISTs were diagnosed as smooth muscle tumors (leiomyoma, leiomyosarcoma and leiomyoblastoma) or tumors of the peripheral nerves (neurofibroma and schwannoma). Nevertheless, the application of immunochemistry has reclassified them. GISTs are mostly found in the stomach (60–70%) and in the small intestine (20–30%). The location in the esophagus and in the colon is about 5% [1, 2]. Extra-gastrointestinal stromal tumors (EGISTs) may occur in the mesentery, omentum and retroperitoneun in about 5% of all cases [3, 4].
The GISTs are usually positive for CD117 (KIT), which is the specific defining immunohistochemical feature for this group of tumors. The accurate surgical resection and the postoperative therapy with the single-agent KIT inhibitor imatinib mesilate (Gleevec, Glivec) is the gold standard treatment for GISTs. Post-operative recurrence is observed in 40–90% of the cases treated with surgery alone .
The differential diagnosis between GISTs and other similar tumors is a challenge. GISTs usually metastasize to the liver and lung, but in recent medical literature an intracranial metastasis from a perisacral GIST has been reported . To the best of our knowledge, metastasis to skeletal muscles and subcutaneous fat has never been described for EGISTs. We present herein, the natural history and gluteal bilateral soft tissue secondary deposits from a misdiagnosed and treated only surgically intrapelvic GIST.
A 56-year old woman was presented to the orthopaedic department with a 3-month history of a painless mass in the upper external area of the left gluteus.
Based on these features, the primary pelvic tumor was most probably an EGIST originally misdiagnosed as leiomyosarcoma. Post-operatively the patient underwent therapy with Imatinib Mesylate (Gleevec, Novartis) and one year after surgery is now free of symptoms.
GISTs are mesenchymal tumors of the gastrointestinal tract, believed to originate from interstitial cells of Cajal or related stem cells. Cajal cells are intermediates between the gastrointestinal (GI) autonomic nervous system and the smooth muscle cells regulating GI motility and autonomic nerve function [7, 8]. Gastrointenstinal mesenchymal tumors (GIMTs) are classified below: a) myogenic tumors that differentiate into smooth muscle cells such as leiomyoma (LM) and leimyosarcoma (LMS), b) neurogenic tumors that differentiate into neurocytes such as schwannoma and c) GIST that differentiate into other cell types. In general, about 80% of GIMT are GIST, 15% are myogenic tumors and 5% are neurogenic tumors [1, 6]
The incidence of GISTs is estimated to be 20/1.000.000 persons per year. The median age of the manifestation ranges between 55 and 65 years of age. These tumors are very rare in individuals before the age of 40 and some studies show a small male predominance [1, 2, 6].
In general the GISTs have a wide clinical manifestation that depends upon the location and the size of the tumor. In colorectal area the tumor may be manifested with lower GI bleeding, perforation, obstruction and pain. The stomach is the most common site of GIST benign tumors, whereas most esophageal and colonic GISTs are malignant . Approximately 20 to 25% of gastric and 40%–50% of small intestinal GISTs, are clinically malignant . GISTs usually metastasize to the liver and lung but in recent publications there have been reports to the skin and brain as sites of metastases . Other case reports described involvement of the omentum, the mesentery and the retroperitoneum, secondary to their GI tract original location [3, 9]. Metastases to the bone and soft tissue are very rare. Miettinen et al. reported humeral metastasis and paraspinal soft tissue involvement in two patients with colonic GIST .
In the case presented herein, the tumor was misdiagnosed and remained untreated for about 4 years. Our hypothesis is that the tumor could have had escaped complete resection from gynecologists either due to small adhesions within the recto-sigmoid area or due to minimal involvement of the gut wall. Histologically a GIST tumor is very similar to leiomyosarcoma (LMS) but in our case non c-KIT positivity was not checked and the tumor was originally diagnosed as uterine leiomyosarcoma. The patient was treated with chemotherapy and radiotherapy but the GISTs are refractory to both . Therefore, we present the natural history of an EGIST localized in pelvis with pulmonary and soft tissue metastasis and a late manifestation from the area of the resected primary.
The differential diagnosis between leiomysarcoma and GIST remains a challenge. Of a total of 133 rectal and anal GISTs identified in the Armed Forces Institute of Pathology at Washington and in the Haartman Institute of the university of Helsinki, 80 tumors (60%) had been originally diagnosed from other centers as leiomyosarcoma (LMSs), 29 tumors (21.8%) as smooth muscle tumors of uncertain malignant potential, 21 tumors (15.8%) as leiomyoma (LMs) and only 3 tumors (2.25%) as GISTs .
Immunohistochemically, the majority of GI mesechymal tumors are GISTs and are strongly c-KIT positive (96–100%) and in particular, esophageal and rectal ones are nearly consistently CD34-positive (95–100%) [1, 6].
Our case may be considered as EGIST. Traditionally the EGIST are mesenchymal tumors with similar clinicopathologic and genetic profile localized in the omentum, mesentery and retroperitoneum comprising less than 5% of GISTs [1, 2]. In the last few years, few cases have been reported in unusual anatomic location [10, 11]. Others suggest that true EGISTs are extremely rare, less than 1,5%, and probably are extramural gastric (omental) or small intestinal (mesenteric) in origin . One of the criteria for diagnosing EGISTs is the recognition of minor association or adhesions with a neighboring gut segment . The prognosis of EGIST, as all GISTs tumors, depends on the mitotic activity, the tumor size, but also the age and location [1, 2, 5]. Gastric tumors have a less aggressive behavior than intestinal tumors. Size larger than 5 cm is also more malignant and a mitotic count over 50/50 HPF demonstrate a high-grade malignancy. Based on these observations our patient had a very aggressive EGIST with high probability for metastasis.
To the best of our knowledge, this is the first case of EGISTs to metastasize bilaterally in the gluteal region. In a retrospective study of 118 metastasis to soft tissues over a period of 30 year, regardless of the primary, 5 cases were located in the gluteal region, all from carcinomas and melanoma. In only one case located to the abdominal wall, the primary tumor was GIST of the small bowel .
Skeletal muscle is resistant to both primary and metastatic cancer. Previous reports have cited various mechanisms as reasons for muscle resistance to malignancy [14–16]. Weiss found that, cancer cells survive best in denervated muscle compared with electrically stimulated muscles . This finding suggests that most cancer cells die soon after haematogenous spread to muscle because of an inhospitable mechanical, pH, and a metabolic environment in normally functioning muscles. Muscles that are injured may have a different mechanical, pH, or metabolic environment that is more favourable to the survival of metastatic cancer cells. We propose that, because of the post-operative radiotherapy, similarly to the muscle injury, the metabolic changes of the gluteal area included in the field of the radiotherapy, probably created a favourable environment for the development of the soft tissue metastasis.
In conclusion, EGISTs are rare tumours of abdominal cavity with potentially high malignancy and metastatic capacity, exhibiting clinical and histological difficulty for a correct diagnosis. Metastatic disease may occur in the soft tissues. Early recognition and prompt diagnosis, will allow the proper treatment to be initiated.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Miettinen M, Lasota J: Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical and molecular genetic features and differential diagnosis. New findings on their biology. Virchows Arch. 2001, 438: 1-12. 10.1007/s004280000338.View ArticlePubMedGoogle Scholar
- Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J: Gastrointestinal stromal tumors and leiomyosarcomas in the colon. A clinicopathologic, immunohistochemical and molecular genetic study of 44 cases. Am J Surg Pathol. 2000, 24: 1339-1352. 10.1097/00000478-200002000-00007.View ArticlePubMedGoogle Scholar
- Miettinen M, Momhan JM, Sarlomo-Rikala M, Kovatich A, Carr NJ, Emory TS, Sobin LH: Gastrointestinal stromal tumors/smooth muscle tumors/GISTs in the omentum and mesentery-Clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol. 1999, 22: 1109-1118. 10.1097/00000478-199909000-00015.View ArticleGoogle Scholar
- Ferchichi L, Kourda N, Zermani R, Aouem J, Zaouche A, Abdjellil Z, Najah N, Baltagi Ben Jilani S: Extragastrointestinal stromal tumors: a report of 4 cases. Ann Chir. 2006, 131: 271-275. 10.1016/j.anchir.2005.09.010.View ArticlePubMedGoogle Scholar
- DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF: Two hundred gastrointestinal stromal tumors: recurrence paterns and prognostic factors for survival. Ann Surg. 2000, 231: 51-58. 10.1097/00000658-200001000-00008.PubMed CentralView ArticlePubMedGoogle Scholar
- Kaku S, Tanaka T, Ohtuka T, Seki K, Sawauchi S, Numoto RT, Murakami S, Komine K, Abe T: Perisacral gastrointestinal stromal tumor with intracranial metastasis. Case report. Neurol Med Chir (Tokyo). 2006, 46: 254-257. 10.2176/nmc.46.254.View ArticleGoogle Scholar
- Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A: W/kit gene required for interstitial cells of cajal and for intestinal pacemaker activity. Nature. 1993, 373: 347-349. 10.1038/373347a0.View ArticleGoogle Scholar
- Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin LH, Lasota J: Gastrointestinal stromal tumors, Intramural leiomyomas and leiomyosarcomas in the rectum and anus. A clinicopathologic, immunohistochemical and molecular genetic study of 144 cases. Am J Surg Pathol. 2001, 25: 1121-1133. 10.1097/00000478-200109000-00002.View ArticlePubMedGoogle Scholar
- Miettinen M, Lasota J: Gastrointestinal stromal tumors: Review on morphology, molecular pathology, prognosis and differential diagnosis. Arch Pathol Lab Med. 2006, 130: 1466-1478.PubMedGoogle Scholar
- Lam MM, Corless CL, Goldblum JR, Heinrich MC, Downs-Kelly E, Rubin BP: Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall. Int J Gynecol Pathol. 2006, 25: 288-292. 10.1097/01.pgp.0000215291.22867.18.View ArticlePubMedGoogle Scholar
- Peitsidis P, Zarganis P, Trichia H, Vorgias G, Smith JR, Akrivos T: Extragastrointestinal stromal tumor mimicking a uterine tumor. A rare clinical entity. Int J Gynecol Cancer. 2008, 18: 1115-8. 10.1111/j.1525-1438.2007.01121.x.View ArticlePubMedGoogle Scholar
- Agaimy A, Wunsch PH: Gastrointestinal stromal tumours: a regular origin in the muscularis propria, but an extremely diverse gross presentation. A review of 200 cases to critically re-evaluate the concept of so-called extra-gastrointestinal stromal tumours. Langenbecks Arch Surg. 2006, 391: 322-9. 10.1007/s00423-005-0005-5.View ArticlePubMedGoogle Scholar
- Plaza JA, Perez-Montiel D, Mayerson J, Morrison C, Suster S: Metastases to soft tissue: a review of 118 cases over a 30-year period. Cancer. 2008, 112: 193-203. 10.1002/cncr.23151.View ArticlePubMedGoogle Scholar
- Acinas Garcia O, Fernandez FA, Satue EG, Buelta L, Val-Bernal JF: Metastasis of malignant neoplasms to skeletal muscle. Rev Esp Oncol. 1984, 31: 57-67.PubMedGoogle Scholar
- Williams JB, Youngberg RA, Bui-Mansfield LT, Pitcher JD: MR imaging of skeletal muscle metastases. AJR Am J Roentgenol. 1997, 168: 555-557.View ArticlePubMedGoogle Scholar
- Pretorius ES, Fishman EK: Helical CT of skeletal muscle metastases from primary carcinomas. AJR Am J Roentgenol. 2000, 174: 401-404.View ArticlePubMedGoogle Scholar
- Weiss L: Biomechanical destruction of cancer cells in skeletal muscle: a rate-regulator for hematogenous metastasis. Clin Exp Metastasis. 1989, 7: 483-491. 10.1007/BF01753809.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.